SNOA — Sonoma Pharmaceuticals, Inc.

Summary of SNOA Q2 2019 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $4.9 million, a record high, reflecting a 14% increase year-over-year and a 13% increase from the previous quarter.
• EBITDA: Loss of $1.95 million, marking a reduction of $313,000 from the same period last year and down $1.1 million (37%) from the prior quarter, indicating progress towards profitability.
• Cash Position: $4 million at the end of the quarter, down from $7.7 million in the previous quarter, primarily due to operating cash burn and working capital increases.
• Prescriptions Filled: 17,410, the highest number ever recorded, up 12% year-over-year and 18% from the previous quarter.

2. Strategic Updates and Business Highlights

• Product Launches: Introduction of the Epicyn Antimicrobial Facial Cleanser in the U.S. and Gramacyn in Brazil, targeting the acne management market, which is valued at over $300 million in the U.S. alone.
• Market Position: Sonoma continues to lead in the manufacturing and sale of hypochlorous acid (HOCl) products, with significant market share in Mexico and growing international revenues.
• Sales Strategy: Increased focus on mail-order pharmacies, which accounted for over 40% of unit sales in the quarter, aimed at reducing inventory risks and improving cash flow.

3. Forward Guidance and Outlook

• Sales Growth: Anticipated growth in sales rep productivity and revenue from new product launches, particularly in the U.S. dermatology and animal healthcare markets.
• Cost Management: Expectation of flat to reduced operating expenses due to ongoing cost reduction initiatives, which should help in further decreasing EBITDA losses.
• International Expansion: Continued growth expected from the Brazilian market with the launch of additional products, supported by a strong local sales force.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: The significant reduction in cash reserves raises concerns about the company's liquidity and ability to fund operations without additional financing.
• Market Pressures: Ongoing challenges in the managed care environment affecting gross-to-net revenue, though management believes they are gaining better control.
• Declining Metrics: A noted decline in dermatology net revenue compared to the previous year, although there was a quarter-over-quarter increase.

5. Notable Q&A Insights

• Mail Order Pharmacy Program: Increased from 20% to over 40% of revenues, indicating a strategic shift that may help stabilize revenues.
• Rebate Situation: Stabilization in rebate costs with effective management strategies in place to control expenses.
• Growth in Brazil: Initial shipments of $248,000 for new products, with expectations for strong growth as additional products are launched.

Overall, Sonoma is making strides towards profitability with record revenues and strategic product launches, although challenges remain in cash management and market pressures. The company remains optimistic about its growth trajectory and operational efficiencies moving forward.